{"description":"Due to the severity of illness in this patient population, this study collected and reported Adverse Events only if at least possibly related to study participation, and only in patients undergoing study intervention (intervention arm).","eventGroups":[{"description":"Group I (observation): Patients with full donor chimerism and no evidence of MRD continue to undergo clinical monitoring for acute and chronic graft-vs-host disease and relapse until 3 years post-transplant. Patients undergo repeat chimerism testing at 12 and 24 months post-transplant.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Group I: Observation"},{"description":"Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.\n\nWithdrawal of immunosuppression and donor lymphocyte infusion: Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.","id":"EG001","otherNumAffected":9,"otherNumAtRisk":26,"seriousNumAffected":1,"seriousNumAtRisk":26,"title":"Group II: Intervention"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":3,"numAtRisk":26,"numEvents":3}],"term":"aGVHD grade I-III"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":2,"numAtRisk":26,"numEvents":2}],"term":"cGVHD"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":4,"numAtRisk":26,"numEvents":4}],"term":"progressive disease"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"severe cGVHD that involved lungs, treated with Prednisone, death due to fungal lung infection","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":26,"numEvents":1}],"term":"intervention-related-death"}],"timeFrame":"2 years"}